V
Vivek Shinde
Researcher at GlaxoSmithKline
Publications - 35
Citations - 2655
Vivek Shinde is an academic researcher from GlaxoSmithKline. The author has contributed to research in topics: Influenza vaccine & Medicine. The author has an hindex of 17, co-authored 28 publications receiving 1943 citations. Previous affiliations of Vivek Shinde include Centers for Disease Control and Prevention.
Papers
More filters
Journal ArticleDOI
Phase 1-2 Trial of a SARS-CoV-2 Recombinant Spike Protein Nanoparticle Vaccine.
Cheryl Keech,Gary Albert,Iksung Cho,Andreana Robertson,Patricia Reed,Susan Neal,Joyce S Plested,Mingzhu Zhu,Shane Cloney-Clark,Haixia Zhou,Gale Smith,Nita Patel,Matthew B. Frieman,Robert Haupt,James Logue,Marisa McGrath,Stuart Weston,Pedro A. Piedra,Chinar Desai,Kathleen Callahan,Maggie Lewis,Patricia Price-Abbott,Neil Formica,Vivek Shinde,Louis Fries,Jason D. Lickliter,Paul M. Griffin,Bethanie E. Wilkinson,Gregory M. Glenn +28 more
TL;DR: At 35 days, NVX-CoV2373 appeared to be safe, and it elicited immune responses that exceeded levels in Covid-19 convalescent serum, and the addition of adjuvant resulted in enhanced immune responses, was antigen dose–sparing, and induced a T helper 1 (Th1) response.
Journal ArticleDOI
Triple-Reassortant Swine Influenza A (H1) in Humans in the United States, 2005–2009
Vivek Shinde,Carolyn B. Bridges,Timothy M. Uyeki,Bo Shu,Amanda Balish,Xiyan Xu,Stephen Lindstrom,Larisa V. Gubareva,Varough M. Deyde,Rebecca Garten,Meghan L. Harris,Susan I. Gerber,Susan Vagasky,Forrest Smith,Neal Pascoe,Karen Martin,Deborah Dufficy,Kathy Ritger,Craig Conover,Patricia Quinlisk,Alexander Klimov,Joseph S. Bresee,Lyn Finelli +22 more
TL;DR: From December 2005 until just before the current human epidemic of swine-origin influenza viruses, there was sporadic infection with triple-reassortant swine influenza A (H1) viruses in persons with exposure to pigs in the United States.
Journal ArticleDOI
Severe Human Influenza Infections in Thailand: Oseltamivir Treatment and Risk Factors for Fatal Outcome
Wanna Hanshaoworakul,James Mark Simmerman,Ubolrat Narueponjirakul,Wiwan Sanasuttipun,Vivek Shinde,Suchada Kaewchana,Darin Areechokechai,Jens W. Levy,Kumnuan Ungchusak +8 more
TL;DR: Severe and fatal human influenza infections were commonly identified in the NAIS designed to identify avian A/H5N1 cases and treatment with Oseltamivir is associated with survival in hospitalized human influenza pneumonia patients.
Journal ArticleDOI
Estimates of mortality attributable to influenza and RSV in the United States during 1997-2009 by influenza type or subtype, age, cause of death, and risk status.
Gonçalo Matias,Robert J. Taylor,François Haguinet,Cynthia Schuck-Paim,Roger Lustig,Vivek Shinde +5 more
TL;DR: Influenza and respiratory syncytial virus (RSV) cause substantial mortality from respiratory and other causes in the USA, especially among people aged 65 and older.
Journal ArticleDOI
The Importance of Frailty in the Assessment of Influenza Vaccine Effectiveness Against Influenza-Related Hospitalization in Elderly People.
Melissa K. Andrew,Vivek Shinde,Lingyun Ye,Todd F. Hatchette,François Haguinet,Gael Dos Santos,Janet E. McElhaney,Ardith Ambrose,Guy Boivin,William R. Bowie,Ayman Chit,Ayman Chit,May Elsherif,Karen Green,Scott A. Halperin,Barbara Ibarguchi,Jennie Johnstone,Kevin Katz,Joanne M. Langley,Jason J. LeBlanc,Mark Loeb,Donna MacKinnon-Cameron,Anne E. McCarthy,Allison McGeer,Jeff Powis,David B. Richardson,Makeda Semret,Grant Stiver,Sylvie Trottier,Louis Valiquette,Duncan Webster,Shelly A. McNeil +31 more
TL;DR: It is found that TIV provided good protection against influenza hospitalization in older adults who were not frail, though VE diminished as frailty increased.